Sienna 102261 COVID-19 Antigen Rapid Test Cassette Instructions
- June 6, 2024
- Sienna
Table of Contents
- Sienna 102261 COVID-19 Antigen Rapid Test Cassette
- INTENDED USE
- PRINCIPLE
- PRECAUTIONS
- SPECIMEN COLLECTION AND PREPARATION
- MATERIALS
- DIRECTIONS FOR USE
- INTERPRETATION OF THE RESULTS
- LIMITATIONS
- PERFORMANCE CHARACTERISTICS
- EXPLANATION OF THE SYMBOLS USED
- REFERENCES
- Read User Manual Online (PDF format)
- Download This Manual (PDF format)
Sienna 102261 COVID-19 Antigen Rapid Test Cassette
A rapid test for the qualitative detection of Novel Coronavirus SARS-CoV-2 antigen in Saliva and/or Nasopharyngeal swab.
For professional in vitro diagnostic use only
Store at 2°C – 30°C (36oF – 86oF)
INTENDED USE
The COVID-19 Antigen Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of COVID-19 antigen in Saliva and Nasopharyngeal swab. The identification is based on the monoclonal antibodies specific for the Nucleocapsid (N) protein of SARS-CoV-2. It is intended to aid in the rapid diagnosis of COVID-19 infections.
Abbreviations
SARS-CoV-2: novel coronavirus
COVID-19: novel coronavirus pneumonia
Summary
The new coronavirus belongs to the coronavirus of the genus β. It has an
envelope and the particles are round or elliptical. They are often polymorphic
and have a diameter of 60-140 nm. Its genetic characteristics are
significantly different from SARS-CoV and MERS-CoV. Current research shows
that the homology with bat SARS-like corona virus (bat-SL-CoVZC45) is more
than 85%. When isolated and cultured in vitro, the new coronavirus can be
found in human respiratory epithelial cells in about 96 hours, while it takes
about 6 days to separate and culture in VeroE6 and Huh-7 cell lines.
The new coronavirus (SARS-COV-2) antigen detection method can effectively
reduce the false negatives of RTPCR and false positives of antibody detection
methods. The diagnosis is fast, accurate and requires low equipment and
personnel, suitable for rapid investigation of suspected cases of novel
coronavirus infection on a large scale.
The rapid investigation of suspected cases is effective during outbreaks and
also can be used as a supplementary test for nucleic acid testing to avoid the
risk of new transmission caused by the discharge of false negative patients.
PRINCIPLE
The COVID-19 Antigen Rapid Test Cassette (Saliva/ Nasopharyngeal Swab) is a
qualitative, lateral flow immunoassay for the detection of the N protein of
SARS-CoV-2 in Saliva and Nasopharyngeal swab. In this test, antibody specific
to the N protein of SARS-CoV-2 is separately coated on the test line regions
of the test cassette.
During testing, the extracted specimen reacts with the antibody to N protein
of SARS-CoV-2 that are coated onto particles. The mixture migrates up the
membrane to react with the antibody to N protein of SARS-CoV-2 on the membrane
and generate one colored line in the test regions. The presence of this
colored line of the test regions indicates a positive result. To serve as a
procedural control, a colored line will always appear in the control region if
the test has performed properly.
REAGENTS
The test cassette contains anti- SARS-CoV-2 Nucleocapsid protein particles and
SARS-CoV-2 Nucleocapsid protein coated on the membrane.
PRECAUTIONS
- For professional in vitro diagnostic use only.
- Follow the instructions for use carefully. Reliability of assay results cannot be guaranteed if there is any deviation from the instructions in this instruction for use.
- The test should remain in the sealed pouch until ready to use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agents.
- Avoid using bloody samples.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection before testing.
- The used tests, specimens and potentially contaminated material should be discarded according to the local regulations.
- Humidity and temperature can adversely affect results.
- Do not store this kit in frozen condition.
- Do not use the product if package is damaged.
- Do not use the product after expiration date.
- Do not re-use the product.
- Use only the extraction solution provided with the kit.
- Read and interpret the results at 10 minutes, do not interpret the results after 20 minutes.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
STORAGE AND STABILITY
Store as packaged at room temperature or refrigerated 2°C – 30°C (36°F –
86°F). The test is stable through the expiration date printed on the sealed
pouch. The test must remain in the sealed pouch until use. DO NOT FREEZE.
Do not use beyond the expiration date.
SPECIMEN COLLECTION AND PREPARATION
The COVID-19 Antigen Rapid Test Cassette (Saliva / Nasopharyngeal Swab) can be performed using Saliva and Nasopharyngeal Swab specimens. The quality of specimens obtained is of extreme importance. Detection of COVID-19 Antigen requires a vigorous and thorough collection technique that provides COVID-19 Antigen rather than just body fluids.
To collect Saliva Specimen:
Use the collection tube to collect saliva. Open the cap of the collection
tube. Install saliva collector, put the collection tube with saliva collector
close to lips and let the saliva flow into the collection tube. The volume of
saliva needs to be between two scale marks (approx. 150-300 μl). If the volume
of saliva is too much, use a dropper to remove the excess saliva until the
final solution is between the two scale marks (approx. 150-300 μl).
To collect Nasopharyngeal swab Specimen:
Insert swab through the nostril parallel to the palate (not upwards) until
resistance is encountered or the distance is equivalent to that from the ear
to the nostril of the patient, indicating contact with the nasopharynx. Swab
should reach depth equal to distance from nostrils to outer opening of the
ear. Gently rub and roll the swab. Leave swab in place for several seconds to
absorb secretions. Slowly remove swab while rotating it. Specimens can be
collected from both sides using the same swab, but it is not necessary to
collect specimens from both sides if the swab is saturated with fluid from the
first collection. If a deviated septum or blockage create difficulty in
obtaining the specimen from one nostril, use the same swab to obtain the
specimen from the other nostril.
MATERIALS
Material Provided
102261
Item number| Content| Quantity
1| Instruction for use| 1 piece
2| Individually Pouched Test Cassettes| 25 cassettes
3| Collection Tubes| 25 tubes
4| Extraction Buffers
(NaCl + Casein Sodium + Tris + Proclin 300)
| 25 tubes
5| Saliva Collectors| 25 pieces
6| Sterile Swabs| 25 pieces
7| Droppers| 25 pieces
8| Workstation| 1 piece
Materials required but not provided
Timer
Gloves
DIRECTIONS FOR USE
Allow the test cassette, specimen, extraction buffer to equilibrate to room
temperature 15°C – 30°C (59°F – 86°F) prior to testing.
For Nasopharyngeal Swab Specimen:
- Remove the test cassette from the sealed foil pouch and use it within one hour. Best results will be obtained if the assay is performed immediately after opening the foil pouch.
- Place the extraction buffer in the workstation. Open the cap of the collection tube. Hold the extraction reagent bottle upside down vertically. Squeeze the bottle and let the solution drop into the extraction tube freely without touching the edge of the tube. Add all extraction buffer (Approx.300μL) to the collection tube.
- Place the swab specimen in the collection tube. Rotate the swab for approximately 10 seconds while pressing the head against the inside of the tube to release the antigen in the swab.
- Remove the swab while squeezing the swab head against the inside of the extraction buffer as you remove it to expel as much liquid as possible from the swab. Discard the swab in accordance with your biohazard waste disposal protocol.
- Tighten cap on the specimen collection tube.
- Add 3 full drops (approx. 80μL) of the solution to the sample well and then start the timer. Avoid trapping air bubbles in the sample well (S). Read the result at 10 minutes. Do not interpret the result after 20 minutes.
For Saliva Specimen
-
Remove the test cassette from the sealed foil pouch and use it within one hour. Best results will be obtained if the assay is performed immediately after opening the foil pouch.
-
Open the cap of the collection tube. Install saliva collector, put the collection tube with saliva collector close to lips and let the saliva flow into the collection tube. The volume of saliva needs to be between two scale marks (approx. 150-300 μl).
-
Place the collection tube with saliva collector (containing the saliva specimen) in the workstation.
Hold the extraction reagent bottle upside down vertically. Squeeze the bottle and let the solution drop into the extraction tube freely without touching the edge of the tube. Add all extraction buffer (Approx. 300μL) to the collection tube. -
Discard the saliva collector, tighten the cap onto the specimen collection tube. Shake the specimen collection tube at least three times vigorously to mix the saliva and the extraction buffer, then squeeze bottom of the collection tube to ensure the saliva is thoroughly mixed.
-
Place the test cassette on a clean and level surface. Add 3 full drops (approx. 80μL) of the solution to the sample well (S) and then start the timer. Avoid trapping air bubbles in the sample well (S). Read the result at 10 minutes. Do not interpret the result after 20 minutes.
INTERPRETATION OF THE RESULTS
9.1| NEGATIVE
One colored line appears in the control line region (C). No line appears in the test line region (T). A negative result indicates that COVID-19 antigen is not present in the specimen, or is present below the detectable level of the test.
|
---|---|---
9.2| **POSITIVE:***
Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T). A positive result indicates that COVID-19 was detected in the specimen.
*NOTE: The intensity of the color in the test line region (T) will vary depending on the concentration of COVID-19 Antigen present in the specimen.
Therefore, any shade of color in the test line region
(T) should be considered positive.
|
9.3| INVALID:
Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact the manufacturer or your supplier.
| ****
QUALITY CONTROL
A procedural control is included in the test. A colored line appearing in the
control line region (C) is considered an internal procedural control. It
confirms adequate membrane wicking.
Control standards are not supplied with this kit; however, it is recommended
that positive and negative controls be tested as good laboratory practice to
confirm the test procedure and to verify proper test performance.
LIMITATIONS
- This device is for professional in vitro diagnostic use only.
- This device is only used for testing human saliva and/or nasopharyngeal swab specimens.
- Neither the quantitative value nor the rate of increase in SAR-CoV-2 virus concentration can be determined by this qualitative test.
- The accuracy of the test depends on the quality of the swab sample. False negatives may result from improper sample collection or storage.
- The COVID-19 Antigen Rapid Test Cassette (Saliva/ Nasopharyngeal Swab) will only indicate the presence of SARS-CoV-2 in the specimen from both viable and non-viable SARS-CoV-2 coronavirus strains.
- As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
- A negative result obtained from this kit should be confirmed by PCR. A negative result may be obtained if the concentration of the SARS-CoV-2 virus present in the sample is not adequate or is below the detectable level of the test.
- Excess blood or mucus on the saliva and/or swab specimen may interfere with test performance and may yield a false positive result.
- A positive result for COVID-19 does not preclude an underlying co-infection with another pathogen, therefore the possibility of an underlying bacterial infection should be considered.
- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
- Positive results may be due to present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
- Results from antigen testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
- Extraction reagent has the ability to kill the virus, but it cannot inactivate 100% of the virus. The method of inactivating the virus can be referred to: what method is recommended by WHO/CDC, or it can be handled according to local regulations.
PERFORMANCE CHARACTERISTICS
Sensitivity, Specificity and Accuracy
The COVID-19 Antigen Rapid Test Cassette (Saliva/ Nasopharyngeal Swab) has
been evaluated with saliva and nasopharyngeal swab specimens obtained from the
patients. RT-PCR is used as the reference method for the COVID-19 Antigen
Rapid Test Cassette (Saliva/ Nasopharyngeal Swab). Specimens were considered
positive if PCR indicated a positive result.
Nasopharyngeal Swab Specimen
Method| RT-PCR| ****
Total Results
---|---|---
SiennaTM COVID-19 Antigen Rapid Test Cassette
| Results| Positive| Negative
Positive| 134| 0| 134
Negative| 7| 162| 169
| Total Results| 141| 162| 303
Relative Sensitivity:| 95.0% (95% CI: 90.0% – 98.0%)
---|---
Relative Specificity:| >99,9% (95% CI: 98.2 – 100.0%)
Relative Accuracy:| 97.7% (95% CI: 95.2% – 99.9%)
Saliva Specimen
Method| RT-PCR| ****
Total Results
---|---|---
SiennaTM COVID-19 Antigen Rapid Test Cassette
| Results| Positive| Negative
Positive| 108| 0| 108
Negative| 12| 162| 174
| Total Results| 120| 162| 282
Relative Sensitivity:| 90.0% (95% CI 83.2% – 94.7%)
---|---
Relative Specificity:| >99.9% (95%CI: 98.2%-100.0%)
Relative Accuracy:| 95.7% (95% CI: 92.7% – 97.8%)
Saliva / Nasopharyngeal Swab Specimen
Method| RT-PCR| ****
Total Results
---|---|---
SiennaTM COVID-19 Antigen Rapid Test Cassette
| Results| Positive| Negative
Positive| 242| 0| 242
Negative| 19| 324| 343
| Total Results| 261| 324| 585
Relative Sensitivity:| 92.7% (95% CI 88.9% – 95.6%)
---|---
Relative Specificity:| >99.9% (95%CI: 99.1%-100.0%)
Relative Accuracy:| 96.8% (95%CI: 95.0%-98.0%)
Limit of Detection
The LOD for the SiennaTM COVID-19 Antigen Rapid Test Cassette(Saliva/
Nasopharyngeal Swab) was established using serial dilutions of an inactivated
viral sample. The material (ZeptoMetrix, 0810587CFHI) was supplied at a
concentration of 1.15 x 107TCID50/mL. The Estimated LOD is 1000 TCID50/mL.
SARS-CoV-2 tested(TCID 50 /mL) | Test Result |
---|---|
1.0×105TCID50/mL | 15/15 Positive |
3.0×103TCID50/mL | 15/15 Positive |
2.0×103TCID50/mL | 15/15 Positive |
1.5×103 TCID50/mL | 15/15 Positive |
1.0×103 TCID50/mL | 15/15 Positive |
7.5×102 TCID50/mL | 15/15 Negative |
Interfering Substance
The following potentially interfering substances were added to SARS-CoV-2
negative and spiked positive specimens. No substances showed any interference
with the test.
Ambroxol Hydrochloride Tablets (7.5 mg/mL)| Nasal antibiotic (Mupirocin
Ointment)
---|---
Mometasone furoate nasal spray (0.05% g/g)| Oxymetazoline Hydrochloride Spray
Herbal cough syrup| Beclomethasone Dipropionate Nasal Aerosol
Dextromethorphan Hydrobromide Oral Solution (1.5 mg/ml)| Triamcinolone
Acetonide Nasal Spray
Mucosolvan Ambroxol Hydrochloride Oral Solution| Azelastine Hydrochloride
Nasal Spray
Nasal cleansing solution, NaCl (5 g/L)| Fluticasone Propionate Nasal Spray
Hyland’s 4 Kids Cold Cough Liquid Safe Natural Relief| Physiological Seawater
Nasal Spray
Durham’s Canker-Rid| Tobramycin Eye Drops
Listerine mouthwash| Whole blood (4%)
Scope mouthwash| Mucin (0.05%)
Bilirubin(10mg/ml)| Triglyceride(5mg/ml)
Hemoglobin(5mg/ml)| HAMA
Cross Reactivity
The following potentially cross-reactive substances were added to SARS-
CoV-2 negative and spiked positive specimens. The organisms or viruses do not
cross-react.
List 1
Potential Cross-Reactant | Concentration | Results |
---|---|---|
Negative Specimen | Spiked with Positive Specimen | |
Parainfluenza Virus Type4a | 1.6×103 TCID50/ml | Negative |
Human Coxsackievirus | 2.8×105 TCID50/ml | Negative |
Mumps virus | 2.8×106 TCID50/ml | Negative |
Rhinovirus | 20 x 109 organisms/ml | Negative |
Haemophilusparainfluenzae | 6×106 bacteria/ml | Negative |
Staphylococcus aureus | 6×106 bacteria/ml | Negative |
Neisseria meningitides | 105 organisms/ml | Negative |
Streptococcus sp. Group A | 108 organisms/ml | Negative |
Streptococcus sp. Group B | 6×106 bacteria/ml | Negative |
Streptococcus sp. Group C | 6×106 bacteria/ml | Negative |
Influenza A Virus H3N2 | CEID50 ≧102 per 0.2 ml | Negative |
List 2
Potential Cross-Reactant | Concentration | Results |
---|---|---|
Negative Specimen | Spiked with Positive Specimen | |
Adenovirus (e.g. C1 Ad. 71)-Type 7A | 2.01 x104 U/ml | Negative |
Enterovirus (e.g. EV68) | 7.16 x104 TCID50/ml | Negative |
Human Metapneumovirus (hMPV) | 5.43 x105 TCID50/ml | Negative |
Influenza A H1N1 (New Cal/20/99) | 1.64 x106 U/ml | Negative |
Influenza B (Florida/02/06) | 2.01 x104 U/ml | Negative |
Parainfluenza virus 1 | 1.30×108 TCID50/ml | Negative |
Parainfluenza virus 2 | 1.64×106 U/ml | Negative |
Parainfluenza virus 3 | 9.44×105 U/ml | Negative |
Parainfluenza virus 4 | 4.03 x106 U/ml | Negative |
Respiratory syncytial virus-Type A | 5.43 x105 U/ml | Negative |
Rhinovirus (Type 1A) | 5.07 x104 U/ml | Negative |
Bordetella pertussis | 1.61 x109 CFU/ml | Negative |
Candida albicans | 8.96 x107 CFU/ml | Negative |
Haemophilus influenzae | 7.76 x107 CFU/ml | Negative |
Legionella pneumophila | 2.69 x109 CFU/ml | Negative |
Mycobacterium tuberculosis | 9.80 x106 CFU/ml | Negative |
Mycoplasma pneumoniae | 4.51 x107 CCU/ml | Negative |
Pneumocystis jirovecii (PJP)-S. cerevisiae Recombinant | 4.93 x107 CFU/ml | |
Negative | Positive | |
Potential Cross-Reactant | Concentration | Results |
--- | --- | --- |
Negative Specimen | Spiked with Positive Specimen | |
Pseudomonas aeruginosa | 1.21 x109 CFU/ml | Negative |
Staphylococcus epidermis | 1.73 x109 CFU/ml | Negative |
Streptococcus pneumoniae | 3.23 x108 CFU/ml | Negative |
Streptococcus pyogenes | 2.34 x108 CFU/ml | Negative |
Streptococcus salivarius | 1.17 x108 CFU/ml | Negative |
Human coronavirus 229E | 5.96 x104 TCID50/ml | Negative |
Human coronavirus OC43 | 1.50 x105 TCID50/ml | Negative |
Human coronavirus NL63 | 2.43 x104 TCID50/ml | Negative |
MERS-coronavirus | 4.51 x105 TCID50/ml | Negative |
List 3
Potential Cross-Reactant | Concentration | Results |
---|---|---|
Negative Specimen | Spiked with Positive Specimen | |
Escherichia coli | 2.0×107 organisms/ml | Negative |
Recombinant Hepatitis C Virus | 1mg/ml | Negative |
Recombinant Hepatitis B Virus | 1 µg/ml | Negative |
Recombinant Cytomegalo virus | 0.066mg/ml | Negative |
Recombinant Epstein-Barr Virus | 0.4mg/ml | Negative |
Recombinant Herpes Simplex Virus-2 (HSV-2) | 0.11mg/ml | Negative |
Recombinant Human Immunodeficiency Virus-1 (HIV-1) | 0.407mg/ml | Negative |
Positive
EXPLANATION OF THE SYMBOLS USED
REFERENCES
-
Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85-164.
-
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17:181-192.
-
Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. TrendsMicrobiol 2016;24:490-502.
-
WHO. Coronavirus disease 2019 (COVID-19) Situation Reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
-
Liu L, Liu W et al. A preliminary study on serological assay for severe acute 2 respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 3 admitted hospital patients. Available from:
https://www.medrxiv.org/content/10.1101/2020.03.06.20031856v1.full.pdf -
UN – COVID-19 FREQUENTLY ASKED QUESTIONS. Available from: https://www.un.org/sites/un2.un.org/files/new_dhmosh_covid-19_faq.pdf
-
Juan juan Zhao et.al, Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clinical Infectious Diseases, ciaa344, http://doi.org/10.1093/cid/ciaa344.
-
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Journal pre-proof DOI:10.1016/
j. cell. 2020.02.058. -
US Food and Drug Administration (FDA). Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff. Issued March 16, 2020. Docket Number FDA-2020- D- 0987.
DATE OF ISSUE
SiennaTM COVID-19 Antigen Rapid Test Cassette insert.
Version 3, April 18th, 2020
GENERAL INFORMATION
Manufacturer:
Salofa Oy
Örninkatu 15, 24100 Salo, Finland
email: info@salofa.com
web: www.salofa.com
Under the licence of:
T&D Diagnostics Canada Pvt. Ltd.
6266 Lawrence Street, Halifax, Nova Scotia, B3L 1J9, Canada
Mail: info@td-diagnostics.com
Web: www.td-diagnostics.com
Read User Manual Online (PDF format)
Read User Manual Online (PDF format) >>